The MEK inhibitor G-38963, along with anti-PD-L1 therapy promotes effector function and lifespan of tumor-infiltrating CD8+ T-cells leading to synergistic inhibition in tumor growth [40]. Here, MAP2K7 is linked to neoplasm.